Drug
PF 3512676
PF 3512676: highest development phase Phase 1/2, developed by Pfizer. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Pfizer
Trials
| Drug | Phase | Indication |
|---|---|---|
| PF-3512676 NCT00043420 | Phase 1/2 | Lymphoma, T-Cell, Cutaneous |
Latest
No recent events.
Follow PF 3512676 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.